雷珠单抗治疗糖尿病黄斑水肿合并黄斑无灌注的疗效:RIDE与RISE研究
本文为RIDE/RISE两项3期随机双盲多中心试验的事后分析,评估基线黄斑无灌注(MNP)对糖尿病黄斑水肿(DME)患者接受雷珠单抗治疗后24个月视力、解剖及糖尿病视网膜病变(DR)结局的影响。结果显示,基线MNP患者虽基线视力更差、黄斑中心凹厚度(CST)更厚、DR更重,但雷珠单抗治疗后视力和解剖改善与无MNP者相当,且≥2步DR改善比例更高,故不应将此类患者排除在治疗之外。
要点
- 基线MNP见于雷珠单抗0.3mg组28.2%、0.5mg组25.8%和假注射组26.3%的研究眼。
- 基线MNP患者更年轻、糖尿病病程更短、视力更差、CST更厚、DR更严重(P值均<0.01)。
- 雷珠单抗0.3mg组中,基线MNP眼24个月视力增益与无MNP眼相当(+15.6 vs +13.4 ETDRS字母,P=0.2)。
核心结论
- 尽管基线MNP患者视力更差、CST更厚,但接受雷珠单抗治疗后仍获得显著的视力与解剖改善,因此不应将其排除在治疗之外。
研究设计与样本
- RIDE/RISE两项3期、平行、随机、多中心、双盲试验的事后分析(ClinicalTrials.gov: NCT00473382; NCT00473330)。
- 纳入基线有最佳矫正视力(BCVA)和荧光素血管造影(FA)数据的研究眼。
- 采用ETDRS网格叠加于黄斑FA,通过软件算法估算中心、内环和外环亚区毛细血管丢失百分比并转换为视盘面积(DA)以测量MNP面积。
主要发现
- 基线MNP在雷珠单抗0.3mg组(n=213)为28.2%、0.5mg组(n=225)为25.8%、假注射组(n=228)为26.3%。
- 基线时,MNP患者更年轻、糖尿病病程更短、视力更差、CST增加、DR严重度更差(与无MNP者比较P值<0.01)。
- 雷珠单抗0.3mg组中,基线MNP眼平均基线BCVA较低(53.4 vs 57.2 ETDRS字母,P=0.05),但24个月平均BCVA增益相当(+15.6 vs +13.4 ETDRS字母,P=0.2)。
- 基线MNP眼基线CST增加,但至24个月时CST下降幅度更大。
- 在每个雷珠单抗治疗组中,基线MNP眼≥2步DR改善的比例高于无MNP眼。
关键数值与推荐
- 基线MNP定义为通过ETDRS网格叠加FA估算的黄斑毛细血管丢失并转换为视盘面积。
- 主要结局包括基线特征、第12和24个月MNP面积、BCVA和CST,以及第3、6、12、18和24个月≥2步DR改善的发生率。
临床怎么用
- 作者认为,合并基线MNP的DME患者不应被排除在雷珠单抗治疗之外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether there are baseline characteristics that distinguish patients with diabetic macular edema (DME) with coexisting macular nonperfusion (MNP) at baseline and assess these patients' potential to achieve favorable visual acuity (VA), anatomic, and diabetic retinopathy (DR) outcomes over 24 months. DESIGN: Post hoc analysis of RIDE/RISE, 2 phase 3, parallel, randomized, multicenter, double-masked trials (ClinicalTrials.gov: NCT00473382; NCT00473330). PARTICIPANTS: Study eyes with best-corrected VA (BCVA)/fluorescein angiogram (FA) data at baseline. METHODS: To measure MNP, the Early Treatment for Diabetic Retinopathy Study (ETDRS) grid was overlaid on FAs of the macula. The MNP area was calculated by estimating the percentage of capillary loss in the central, inner, and outer subfields and converting into disc areas (DAs) using a software algorithm. Summary statistics and P values, respectively, were provided for all outcomes and comparisons of interest. MAIN OUTCOME MEASURES: Baseline characteristics; MNP area, BCVA, and central subfield thickness (CST) at months 12 and 24; and incidence of study eyes with ≥2-step DR improvement at months 3, 6, 12, 18, and 24. RESULTS: Baseline MNP was detected in 28.2%, 25.8%, and 26.3% of study eyes in the ranibizumab 0.3 mg (n = 213), ranibizumab 0.5 mg (n = 225), and sham (n = 228) arms, respectively. At baseline, patients with MNP were younger and had shorter diabetes duration, worse vision, increased CST, and worse DR severity (P values < 0.01 vs. those without MNP). In the ranibizumab 0.3 mg arm, eyes with baseline MNP had lower mean baseline BCVA (53.4 vs. 57.2 ETDRS letters for those without baseline MNP; P = 0.05), but mean BCVA gain at month 24 was comparable (+15.6 vs. +13.4 ETDRS letters, respectively; P = 0.2). Eyes with baseline MNP had increased CST at baseline, but experienced a greater decrease in CST by month 24. The proportion of eyes with ≥2-step DR improvement was greater for eyes with versus without baseline MNP in each ranibizumab arm. CONCLUSIONS: Despite having worse vision/increased CST versus those without baseline MNP, eyes with concurrent DME and baseline MNP entering RIDE/RISE experienced robust VA and anatomic improvement with ranibizumab and therefore should not be excluded from therapy.
引用
- Reddy RK, Pieramici DJ, Gune S, et al. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE. Ophthalmology. 2018. PMID: 29752001. doi:10.1016/j.ophtha.2018.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。